Algernon Pharmaceuticals Inc.

Clinical Stage Drug Development Company

Projecting Phase 2 Data – Q2, 2022 for Idiopathic Pulmonary Fibrosis & Chronic Cough Study


Lead Program Includes Investigating the Psychedelic Drug DMT for Stroke